Similar results were shown in another study demonstrating a 10-year cumulative contralateral breast cancer risk of 23.9% (BRCA1: 25.5%; BRCA2: 17.2%) in patients <41 years, compared to 12.6% in the 41–49 year group (BRCA1 15.6%; BRCA2 7.2%) [15]. This evidence concerns the gene BRCA2 and breast carcinoma.